Business Wire

AROMA-BIT

Share
Aroma Bit to Develop Smartphone Embeddable Ultra-compact Silicon CMOS Based Smell Sensor That Has Dog Nose Equivalent Resolution in 1mm Squared Die Size

Aroma Bit launched a new subsidiary to develop the next generation smell sensor based on silicon CMOS sensor substrate that are ultra-compact, high resolution and low cost. The technology is realized by applying Aroma Bit developed smell sensor receptor membrane technology to ultra-sensitive silicon CMOS based ion imaging sensor technology developed by professor Kazuaki Sawada at Toyohashi University of Technology and associated companies.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190722005004/en/

Aroma Bit: http://www.aromabit.com

Realizing smartphone embeddable smell sensor with dog nose equivalent ultra-high resolution smell sensor on only 1 millimeter square silicon die size

Aroma Bit has developed and are currently selling a compact smell sensor that employs QCM or Quartz Crystal Microbalance type sensor substrate, which demonstrates ultra-high sensitivity in the sensor market. However, further size reduction, cost reduction to meet high volume application market, such as smartphone, was challenging with conventional QCM type smell sensor.

With the newly developed silicon CMOS type smell sensor, ultra-compact, high smell resolution and low cost can be realized, to be embedded to system such as smartphone or IoT devices. For instance, it is expected that resolution equivalent to dog nose’s resolution (roughly 1,200 receptors) within 1mm die size can be achieved using the new type of sensor substrate.

With new addition of sensor substrate technology, Aroma Bit now holds two types of sensor substrate technology line up: (1) conventional and yet ultra-high sensitivity QCM type sensor substrate technology, and (2) ultra-high resolution, ultra-compact, low cost silicon CMOS type sensor substrate technology. Combined, highly competitive sensor technology portfolio is realized in two key performance for smell sensor, namely, sensor sensitivity and smell resolution. As a result, the addition of the new sensor is expected to further enhances Aroma Bit’s technology competitive advantage against its competitors in the compact smell sensor space.

Aroma Bit is currently also accelerating its development of digital smell database or smell big-data based on its hardware competitive advantage. Sensor hardware and smell database together, Aroma Bit is committed to retain its top-position in growing digital olfactory market, thereby realizing Aroma Bit’s vision “to realize a better world by visualizing the world of smell/aroma through odor imaging technology.”

New subsidiary certified as the first Toyohashi University of Technology University- Launched Venture Company

The new developed subsidiary, Aroma Bit Silicon Sensor Technology, Inc., is certified as the first Toyohashi University of Technology certified University-Launch Venture Company.

While University-Launched Venture company is on the rise in Japan, there is limited successful case leading to industrialization, due to factors such as lack of intellectual property conflict among large companies interest, skill set mismatch on researcher as entrepreneurs, among others.

In this particular Industry-academia collaboration case, the chance to commercialize technology is expected to increase by assigning venture company a role to drive business development of the technology developed jointly with university.

Background:

Aroma Bit succeeded in developing next generation smell sensor based on silicon CMOS sensor substrate that are ultra-compact and high resolution by applying Aroma Bit developed smell sensor receptor membrane technology to ultra-sensitive silicon CMOS based ion imaging sensor technology developed by professor Kazuaki Sawada at Toyohashi University of Technology.

In 2017, Toyohashi Technology of University, Toyohashi Sensor Kyogikai Corporation, Hamamatsu Photonics K.K., Toho Technology Corporation, Nippon Chemi-con Corporation and Aroma Bit together formed private Consortium COSCo (CMOS Odor Sensor Consortium). In 2018, COSCo consortium released working prototypes such as Kaori-Camera (Aroma Camera) and i-sniffer.

In the interest to aggregate the achievement from COSCo consortium and further accelerate development and industrialization, Aroma Bit Silicon Sensor Technology, Inc. (Hereafter, “ABSST”) is founded as Aroma Bit’s subsidiary.

Going forward, ABSST is committed to develop the silicon CMOS type next generation smell sensor that are ultra-high resolution, ultra-compact and low-cost embeddable to smartphone and IoT Devices.

New Subsidiary Company Profile

Name of company:

Aroma Bit Silicon Sensor Technology Inc. (ABSST)

Date of Registration:

June 28th, 2019

Paid-in-Capital:

10 Million JPY [Aroma Bit, Inc. Subsidiary]

Business Profile:

Planning, Development, Manufacturing and Sales of silicon CMOS based next generation smell, gas sensor, and other related business

Representative Management:

Representative Director & CEO Shunichiro Kuroki [Current Representative Director & CEO of Aroma Bit, Inc.]

Address:

E205 KSP 3-2-1 Sakado, Takatsu-ku, Kawasaki-city, Kanagawa 213-0012 [Aroma Bit Kawasaki Lab]

Corporate URL:

www.aromabitsst.com

Contact:

Email: info@aromabitsst.com
Tel: + 81-3-6434-0365

About Aroma Bit

Aroma Bit develops, produces and sells electronic equipments and systems including compact odor imaging sensors.

[Corporate summary]

Name:

Aroma Bit, Inc.

Address:

Sagami Building 2F 7-13-6 Ginza, Chuo-ku, Tokyo

Representative:

Representative Director & CEO Sunichiro Kuroki

Established:

February, 2014

Business:

- Development, Production and Sales of electronic equipments and systems including compact odor imaging sensors.

- Development, Production and Sales of innovative services using the Sensor products.

 

- Other business related to the above.

Corporate URL:

www.aromabit.com

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

TreeFrog Therapeutics Announces Changes to Executive Committee With the Arrival of Mark Rothera as Chief Executive Officer & Board Member to Spearhead Next Phase of Growth16.12.2025 09:05:00 CET | Press release

TreeFrog Therapeutics, a French biotech focused on bringing regenerative medicine to millions through their proprietary cell technology, C-Stem™ is delighted to announce the appointment of skilled biotech leader, Mark Rothera, as Chief Executive Officer and Board member. He succeeds Frédéric Desdouits, who is stepping down after five years in the role. In the new leadership configuration, co-founders Kévin Alessandri and Maxime Feyeux will transition from daily operations to focus on their roles on the Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251215145193/en/ Mark Rothera, CEO TreeFrog Therapeutics Elsy Boglioli, Chair of the Board of TreeFrog Therapeutics, commented “On behalf of the Board, we are delighted to welcome Mark to TreeFrog. His 30+ years of biopharma leadership, including most recently, three biotech CEO roles in gene therapy and biologics, will be invaluable as we advance our Parkinson’s and liver

RoslinCT and Ayrmid Ltd. Announce Expansion of Strategic Partnership to Manufacture Omisirge® (omidubicel-onlv) for Second FDA-Approved Indication in Severe Aplastic Anemia (SAA)16.12.2025 09:00:00 CET | Press release

RoslinCT is performing technology transfer and will support commercial manufacture of Omisirge® for an additional indication following successful clinical trialsOmisirge® now FDA-approved for an expanded patient population in hematologyRoslinCT continues to support and advance multiple cell therapy projects at its Hopkinton, MA facility Ayrmid Ltd., the parent company of Gamida Cell Inc., a pioneering cell therapy company transforming cells into powerful therapeutics, and RoslinCT, a global leader in cell and gene therapy contract development and manufacturing, today announced the expansion of their strategic partnership to include the execution of a commercial supply agreement to support production of Omisirge® (omidubicel-onlv). Following positive clinical trial results, Omisirge® has received FDA approval for a second indication, broadening its use in the treatment of hematology patients. Under the commercial supply agreement, RoslinCT will complete technology transfer and support c

Echoworx Secures FSQS-Netherlands Certification, Strengthening Trust in Financial Data Protection16.12.2025 07:00:00 CET | Press release

Leading encryption provider deepens commitment to European financial sector with rigorous new supplier qualification, building on existing UK & Ireland certification. Echoworx, a global leader in email and data encryption, proudly announces it has achieved Financial Services Qualification System (FSQS) registered supplier status for the Netherlands. This certification powerfully demonstrates Echoworx’s commitment to the highest standards of security and compliance. This achievement expands on the company’s existing FSQS certification for the UK and Ireland, secured in 2020. By successfully completing the rigorous qualification for the Netherlands, Echoworx reinforces its alignment with the stringent demands of the European financial market. The FSQS system, managed by Hellios, provides a single, reliable standard for vetting third-party suppliers, streamlining procurement for major banks and financial institutions. Think of FSQS as a high-security passport for technology partners. It p

Nippon Electric Glass to Start World’s First Mass Production of Low-Carbon Pharmaceutical Glass Tubing Using an All-Electric Furnace16.12.2025 03:00:00 CET | Press release

Nippon Electric Glass Co., Ltd. (NEG)(TOKYO:5214), a global leader in specialty glass headquartered in Otsu, Japan, announced it will begin the world’s first mass production of pharmaceutical-grade glass tubing using an all-electric melting furnace. Commercial production is scheduled to start in December 2025 at its subsidiary in Selangor, Malaysia. This breakthrough introduces a new manufacturing model for pharmaceutical packaging. By combining NEG’s proprietary all-electric melting technology with renewable energy, CO2 emissions from glass tubing production can be reduced by up to 90%*1 compared with conventional fossil-fuel combustion furnaces. This positions NEG as a major supplier capable of delivering both high-performance borosilicate glass and a significantly lower carbon footprint, directly addressing global sustainability demands from pharmaceutical companies and regulators. NEG is a leading global supplier of arsenic-free, environmentally friendly borosilicate glass tubing f

Esco Aster Signs Exosome Clinical cGMP Manufacturing Contract With Shine-On Biomedical For A Novel First-In-Class HLA-G Targeting Exosome Drug Delivery Platform16.12.2025 02:00:00 CET | Press release

Esco Aster, a vertically integrated cell and derivatives CRDMO based at JTC LaunchPad Singapore, announced CMC manufacturing support for Shine-On Biomedical’s HLA-G targeted exosome program. Shine-On Biomedical sponsored Esco Aster in 2023 for cGMP services, starting with high-yield exosome development using Esco Aster’s cell line platform. The technical reports of process, analytical, and formulation development, exosome drug loading, GMP engineering runs, and stability studies supported Shine-On’s IND submission. The IND was cleared by the U.S. FDA in Q1 2025. Furthermore, Esco Aster is providing technical services for exploratory exosome loading feasibility studies per Shine-On’s instruction. Shine-On Biomedical is an emerging innovator in exosome-based drug delivery. ShineOn’s proprietary product, SOB100, a HLA-G targeted exosome drug delivery carrier, has passed the U.S. FDA IND review and ongoing Phase I study, making it as a first-in-class–potential HLA-G targeted exosome platfo

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye